USPTO has published Phosphagenics’ application for a Pharmaceutical Formulation patent which is intended to protect the use of TPM in a broad range of injectable formulations (Pub. No: 20190015329, Pub. Date: 17/01/19). This patent, along with a joint Phosphagenics-Terumo patent specifically for TPM/Propofol, was referred to by the company in a November 2017 update.
The TPM formulation is described as suitable for topical, enteral or parenteral administration, but is considered particularly suitable as an injectable formulation.
https://www.uspto.gov/
- Forums
- ASX - By Stock
- POH
- Terumo and Propofol Injectable
Terumo and Propofol Injectable, page-118
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
POH (ASX) Chart |
Day chart unavailable